ANIKAnika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and ser…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH. | ||
 5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally. | ||
 MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain. | ||
 Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out. | ||
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029. | ||
 Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO Recent price strength puts OptimumBank, EuroDry, Enova International, Anika Therapeutics and GEO in focus as August stocks with momentum. | ||
 5 Stocks With Recent Price Strength to Tap August Rally Five stocks, including OPHC, EDRY, ENVA, ANIK and GEO, show strong recent price gains and earnings growth as markets rally. | ||
 Anika (ANIK) Q2 2026 Earnings Call Transcript Revenue hit $32.6 million with record commercial channel sales and expanded margins. | ||
 Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. | ||
 Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher Guidance The latest analyst update on Anika Therapeutics centers on a higher price target, with modeled fair value moving from US$16 to US$21 per share. Research commentary describes this shift as a reflection of greater confidence in the company’s ability to sustain profitability, supported by the recent Q2 beat, stronger margins, and raised guidance. As you read on, you will see how this evolving narrative is taking shape and what to watch to stay in step with it. Stay updated as the Fair Value for... | ||
 These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook. | ||
Anika Therapeutics Inc (ANIK) Q2 2026 Earnings Call Highlights: Record Revenue and Margin ... Anika Therapeutics Inc (ANIK) reports robust growth in commercial and international channels, while navigating pricing pressures and regulatory uncertainties. | ||
 Anika Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call | ||
 Anika Therapeutics Q2 Earnings Call Highlights Anika Therapeutics (NASDAQ:ANIK) reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and manufacturing improvements supported profitability. Total revenue rose 16% year over year to $32.6 million | ||